# POST-INTUBATION ANALGESIA AND SEDATION

# Intubated patients experience pain and anxiety

- Mechanical ventilation, endotracheal tube
- Blood draws, positioning, suctioning
- Surgical procedures, dressing changes
- Awareness during neuromuscular blockade
- Invasive catheters
- Loss of control



# Unrelieved pain and anxiety cause adverse effects

- Self-injury and removal of life-sustaining devices
- Increased endogenous catecholamines
- Sleep deprivation, anxiety, and delirium
- Impaired post-ICU psychological recovery
- Emotional and posttraumatic effects
- Ventilator dysynchrony
- Immunosuppression

# Treating pain and anxiety improves outcomes

- Use of pain and sedation scales in critically ill patients allows:
  - precise dosing
  - reduced medication side effects
  - reduced ICU and hospital length of stay
  - shorter duration of mechanical ventilation
- Analgesics should be provided first, then anxiolysis

If you were intubated, how much lorazepam or midazolam, and fentanyl would you want per hour?



# Intubated ED patients receive inadequate analgesia and sedation

- □ Retrospective study, tertiary ED
- 50% received no analgesia, 30% received no anxiolytic
- Of patients receiving postintubation vecuronium,
   96% received either no or inadequate anxiolysis or analgesia
- Overall, 3 of 4 patients received no or inadequate analgesia and an equivalent number received no or inadequate anxiolysis

# Analgesia: opioids

- Bind CNS and peripheral tissue receptors
  - Mu-1 receptors: analgesia
  - Mu-2 receptors: respiratory depression, vomiting, constipation, and euphoria
  - Kappa receptor: sedation, miosis, and spinal analgesia

# Analgesia: opioids

- Provide mild anxiolysis, but no amnesia
- Help palliate coughing and subjective sense of dyspnea
- Little cardiovascular effect in euvolemic patients
  - In hypovolemic patients with reduced cardiac output, decreased in venous return, reduced sympathetic tone, and reduction in heart rate can result in hypotension.

## Morphine

- □ Poorly lipid soluble
- □ Slow onset (5-10 min)
- $\Box$  T  $\frac{1}{2}$  4 hrs
- Not preferred in hepatic or renal insufficiency
  - Resultant hepatic glucuronide metabolite is 20x more active than morphine
  - Eliminated renally

### Remifentanil

- Highly lipophilic
- Rapid onset (seconds)
- $\Box$  T  $\frac{1}{2}$  = 3.2 min
- Metabolized by widespread esterases to clinically inactive metabolites
- Relatively new drug; ICU use only
- Risk hyperalgesia and consequences of very abrupt withdrawal of analgesia

# Fentanyl

- Highly lipophilic
- Rapid onset (1 min)
- $\Box T \frac{1}{2} = 1 \text{ hr}$
- Large volume of distribution into tissues
  - Risk of accumulation
- Good choice in renal insufficiency
  - Hepatic metabolism creates inactive metabolites which are renally excreted

#### Sedation

- Provide analgesia first
- Supplement with sedation
- Exception: during use of neuromuscular blocking agents
  - Deep sedation (amnesia) is required to avoid an awake but paralyzed patient.

## Benzodiazepines

- Work on the neuroinhibitory g-aminobutyric acid
   (GABA) receptor
- Anxiolytic, sedative, and hypnotic effects at increasing doses
- Antiepileptic properties

## Benzodiazepines

- Two most common: midazolam and lorazepam
- Both lipophilic, although midazolam is more so in plasma (thus, more rapid onset (<1 min) than lorazepam)
- Hepatically metabolized via the CYP450 enzyme
- Lorazepam preferred in renal failure due to inactive metabolites, whereas midazolam metabolites are active
- Both generally safe and effective short-term sedatives
- ICU considerations
  - Accumulation in adipose tissues, propylene glycol toxicity from lorazepam vehicle, delirium

### Sedation

- Worse outcomes with benzodiazepines compared to propofol or dexmedetomidine
  - Delirium, oversedation, delayed extubation, and longer time to discharge

## Propofol

- Unclear mechanism; GABAergic and direct effects on the brain
- Powerful anxiolytic and amnestic
  - Provides no analgesia
- □ Lipophilic; onset in seconds to minutes
- Rapid (minutes) redistribution to peripheral tissues
   and a large volume of distribution

## Propofol

- Preferred in traumatic brain injury
  - May decrease cerebral oxygen consumption
  - May reduces intracranial pressure
  - Antiepileptic
  - Allows for serial neurologic assessments due to rapidity of action, ease of titration, and lack of active metabolites
- Can cause hypotension, particular if in under volumeresuscitated patients
- ICU considerations
  - Hypertriglyceridemia, propofol infusion syndrome

#### Dexmedetomidine

- □ Central α2 agonist
  - Similar to clonidine, but more specific for the receptor
- Lipophilic
- New sedative and analgesic without respiratory depression; provides lighter sedation
- Side effects
  - Bradycardia and hypotension
  - Can be mitigated by avoiding a loading dose and initiating a slow infusion rate
- □ ICU use

#### Ketamine

- Unique analgesic and anesthetic agent
- Phencyclidine derivative, produces a "dissociative" state
- Prevents bronchoconstriction induced by histamines
- Directly relaxes bronchial smooth muscle
- Multifactorial mechanism of action; acts centrally and increases catecholamine levels
- Lowers airway resistance, increases lung compliance, increases airway secretions
- Increase oxygenation, decreases hypercarbia
- Rapidly acting; plasma T  $\frac{1}{2}$  7-11 minutes, tissue T  $\frac{1}{2}$  2-3 hours
- Metabolized hepatically to active metabolites

#### Ketamine

- Due to sympaticomimetics effects, contraindicated in hypertension, cardiovascular disease, high intracranial pressure (controversial), preeclampsia, glaucoma, and history of psychosis
- Other side effects: lowering of the seizure threshold, altered mood, delirium, laryngospasm, and aspiration
- Has been used for RSI and sedation in severe, decompensating asthmatics refractory to maximal medical therapies
- Infusion rate: 1 mg/kg/hr IV
- May need to treat hypersalivation with adjunctive atropine or glycopyrrolate

### Recommendations

# Analgesia

- Continuous Fentanyl infusion
  - □ Initial IV bolus of 50–100 mcg, followed by an infusion of 25–100 mcg/h
- Consider using an established sedation scale to monitor patient comfort (e.g. RASS)

### Sedation

- Consider hemodynamics, renal or hepatic insufficiency
- Continuous infusions:
  - □ Propofol: initial bolus 0.25-1 mg/kg followed by an infusion of 25 75 mcg/kg/min
  - Lorazepam 0.5 –2.0 mg/hr IV drip
  - Midazolam 1-6 mg/hr IV drip or 2-5 mg IVP q 60 min
  - Dexmedetomidine infusion: 0.2-1.4 mcg/kg/hr

#### EM guideline draft

25-75 mcg/kg/min

<120 or MAP<90

neurologic assessments

#### Post-intubation analgesia and sedation

#### Inclusion criteria: Intubated adults in the ED Document patient weight, allergies Optimize hemodynamics Assess for renal or hepatic insufficiency Ensure deep sedation and amnesia if neuromuscular blockade must be used Provide analgesia Continuous Fentanyl infusion: Initial IV bolus of 50-100 mcg, followed by an infusion of 25-100 mcg/h Titrate to pain relief Good choice in renal insufficiency Provide sedation Continuous Propofol infusion: Initial bolus Continuous Lorazepam Continuous Midazolam Continuous Dexmedetomidine infusion: 0.25-1 mg/kg followed by an infusion of infusion: 0.5 -2.0 mg /hr IV infusion: 1-6 mg /hr IV drip drip or-intermittent 2-5 mg IV 0.2-1.4 mcg/kg/hr Maximum dose is 80 mcg/kg/min Better choice than midazolam bolus q 60 min Monitor for hypotension and Reduce propofol infusion dosing by 1/2 if SBP in renal insufficiency Active metabolites accumulate bradycardia in renal failure No initial bolus Preferred in suspected TBI; allows for serial Monitor vitals, continued reassessment


This guideline was ratified by the emergency department faculty at Maine Medical Center in June 2012. It reflects our expert opinion and is not necessarily applicable to all institutions. It is intended to be a reference for clinicians caring for patients and is not intended to replace providers' clinical judgment.

Consider use of an institutional ICU sedation scale for titration If respiratory distress develops, anxiety is a diagnosis of exclusion

Produced by Julie Pelletier, MD, and

#### EM guideline draft minus dex

#### Post-intubation analgesia and sedation



This guideline was ratified by the emergency department faculty at Maine Medical Center in June 2012. It reflects our expert opinion and is not necessarily applicable to all institutions. It is intended to be a reference for clinicians caring for patients and is not intended to replace providers' clinical judgment.

Produced by Julie Pelletier, MD, and

#### References

- Barr J, Donner A. Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Crit Care Clin. 1995 Oct;11(4):827-47.
- Bonomo JB, et al. Inadequate provision of postintubation anxiolysis and analgesia in the ED. Am J Emerg Med. 2008 May;26(4):469-72.
- Brush DR, Kress JP. Sedation and analgesia for the mechanically ventilated patient. Clin Chest Med. 2009 Mar;30(1):131-41.
- Gerlach AT, et al. An Updated Focused Review of Dexmedetomidine in Adults. Ann Pharmacother 2009;43:2064-74.
- Gommers D, Bakker J. Medications for analgesia and sedation in the intensive care unit: an overview. Crit Care. 2008;12 Suppl 3:S4.
- Hogarth DK, Hall J. Management of sedation in mechanically ventilated patients. Curr Opin Crit Care. 2004 Feb;10(1):40-6.
- Honiden S, Siegel MD.Analytic reviews: managing the agitated patient in the ICU: sedation, analgesia, and neuromuscular blockade. J Intensive Care Med. 2010 Jul;25(4):187-204.
- Patel SB, Kress JP. Sedation and analgesia in the mechanically ventilated patient. Am J Respir Crit Care Med. 2012 Mar 1;185(5):486-97.
- Schweickert WD, Kress JP. Strategies to optimize analgesia and sedation. Crit Care. 2008;12 Suppl 3:S6. Epub 2008 May 14. Review.
- Strøm T, et al. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet. 2010 Feb 6;375(9713):475-80.
- University of Cinncinati. CPQE: Post RSI Management. April 2009
- □ Wood S, Winters ME. Care of the intubated emergency department patient. J Emerg Med. 2011 Apr;40(4):419-27.